ID28053A - Perlakuan asam nukleat enzimatis pada penyakit-penyakit atau kondisi-kondisi yang berkaitan dengan infeksi virus hepatitis c - Google Patents

Perlakuan asam nukleat enzimatis pada penyakit-penyakit atau kondisi-kondisi yang berkaitan dengan infeksi virus hepatitis c

Info

Publication number
ID28053A
ID28053A IDW20002466A ID20002466A ID28053A ID 28053 A ID28053 A ID 28053A ID W20002466 A IDW20002466 A ID W20002466A ID 20002466 A ID20002466 A ID 20002466A ID 28053 A ID28053 A ID 28053A
Authority
ID
Indonesia
Prior art keywords
nucleatic
hepatitic
diseases
treatment
virus infection
Prior art date
Application number
IDW20002466A
Other languages
English (en)
Inventor
Lawrence Blatt
James A Mcswiggen
Elisabeth Roberts
Pamela A Pavco
Dennis Macejak
Original Assignee
Ribozyme Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/274,553 external-priority patent/US20020082225A1/en
Application filed by Ribozyme Pharm Inc filed Critical Ribozyme Pharm Inc
Publication of ID28053A publication Critical patent/ID28053A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
IDW20002466A 1998-04-27 1999-04-26 Perlakuan asam nukleat enzimatis pada penyakit-penyakit atau kondisi-kondisi yang berkaitan dengan infeksi virus hepatitis c ID28053A (id)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8321798P 1998-04-27 1998-04-27
US10084298P 1998-09-18 1998-09-18
US25760899A 1999-02-25 1999-02-25
US09/274,553 US20020082225A1 (en) 1999-03-23 1999-03-23 Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis c virus infection

Publications (1)

Publication Number Publication Date
ID28053A true ID28053A (id) 2001-05-03

Family

ID=27491784

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002466A ID28053A (id) 1998-04-27 1999-04-26 Perlakuan asam nukleat enzimatis pada penyakit-penyakit atau kondisi-kondisi yang berkaitan dengan infeksi virus hepatitis c

Country Status (8)

Country Link
EP (1) EP1075508A2 (id)
JP (1) JP2002512791A (id)
KR (1) KR20010043111A (id)
CN (1) CN1312856A (id)
AU (1) AU757034B2 (id)
CA (1) CA2326695A1 (id)
ID (1) ID28053A (id)
WO (1) WO1999055847A2 (id)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
AU2003219432B2 (en) * 2002-03-27 2010-04-01 Pharmascience Inc. Antisense IAP nucleobase oligomers and uses thereof
KR100490699B1 (ko) * 2002-10-05 2005-05-19 제노프라 주식회사 씨형 간염 바이러스의 아이알이에스 발현 세포에서만 선택적으로 유전자 활성을 유도하는 트랜스-스플라이싱 리보자임
US7364854B2 (en) * 2004-01-23 2008-04-29 Biomerieux, Inc Nucleotide mixture for improved nucleic acid amplification performance

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus

Also Published As

Publication number Publication date
AU757034B2 (en) 2003-01-30
WO1999055847A2 (en) 1999-11-04
EP1075508A2 (en) 2001-02-14
CA2326695A1 (en) 1999-11-04
KR20010043111A (ko) 2001-05-25
JP2002512791A (ja) 2002-05-08
AU3665799A (en) 1999-11-16
WO1999055847A3 (en) 2000-06-15
CN1312856A (zh) 2001-09-12

Similar Documents

Publication Publication Date Title
ATE315938T1 (de) 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen
ATE247987T1 (de) Behandlung zur beseitigung von gerüchen
ATE230999T1 (de) Kombinationstherapie zur entfernung von nachweisbarer hcv-rns in patienten mit chronischer hepatitis c-infection
DE60130723D1 (de) Implantierbarer Herzschrittmacher zur Optimierung der Reizungseffektivität
NO20032271D0 (no) GABA-enhancere i behandlingen av sykdommer relatert til redusert nevrosteroidaktivitet
ATE306481T1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
EP1499333A4 (en) PROCESS FOR TREATING ILEUS
ATE481981T1 (de) Behandlung von infektionen des verdauungstrakts mit enzymen
ATE296040T1 (de) Luftdurchlässige bekleidung zur komfortverbesserung des menschlichen körper
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
ID27576A (id) Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun
EE04055B1 (et) Ühendid ja kompositsioonid seriinproteaasse, eriti trüptaasse aktiivsusega seotud haiguste raviks, ja nende kasutamine
NO20011789D0 (no) Ribavirin-interferon-<alfa>-kombinasjonsterapi for utryddelse av påvisbar HCV-RNA i pasienter med kronisk hepatitt C-infeksjon
DE60127552D1 (de) Intrakorporelle medikamente zur hoch-energetischen phototherapeutischen behandlung von krankheiten
ID28053A (id) Perlakuan asam nukleat enzimatis pada penyakit-penyakit atau kondisi-kondisi yang berkaitan dengan infeksi virus hepatitis c
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
GB9912639D0 (en) Improvements in and relating to treatment of respiratory conditions
EP1507523A4 (en) Cinnamic acid dimers, their preparation and their use in the treatment of neurodegenerative diseases
PT1097159E (pt) Utilizacao de derivados de acidos fosfinicos e fosfonicos como medicamentos
DE60043648D1 (de) Medikamente zur behandlung von periodontalen erkrankungen
NO20010044L (no) Anvendelse av texafyriner i makrofag-medierte sykdommer
ATE295159T1 (de) Bupropion zur behandlung von viralen erkrankungen
DE60114448D1 (de) Imidazolonderivate zur behandlung viraler krankheiten
ID29777A (id) S-nitrosotiol sebagai zat-zat untuk pengobatan gangguan fungsi peredaran darah